HOSPITAL UNIVERSITARIO QUIRÓNSALUD MADRID
Departamento
AstraZeneca (United Kingdom)
Cambridge, Reino UnidoPublicaciones en colaboración con investigadores/as de AstraZeneca (United Kingdom) (8)
2023
-
Chronic Airways Assessment Test: psychometric properties in patients with asthma and/or COPD
Respiratory Research, Vol. 24, Núm. 1
-
Cluster Analyses From the Real-World NOVELTY Study: Six Clusters Across the Asthma-COPD Spectrum
Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 9, pp. 2803-2811
-
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials
The Lancet Child and Adolescent Health, Vol. 7, Núm. 3, pp. 180-189
-
Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease
Journal of the Pediatric Infectious Diseases Society, Vol. 12, Núm. 8, pp. 477-480
-
Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy
Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 6, pp. 1759-1770.e7
2022
-
Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity
New England Journal of Medicine
-
The burden of mild asthma: Clinical burden and healthcare resource utilisation in the NOVELTY study
Respiratory Medicine, Vol. 200
-
Treatable traits in the NOVELTY study
Respirology, Vol. 27, Núm. 11, pp. 929-940